n = number of struts analyzed

a. BIOTRONIK data on file (n = 5), based on statistically significant differences on the bench for Pushability, Trackability, and Crossability compared to Xience Skypoint, superior to Xience in STEMI patients; b. ø 2.25 – 3.0 mm strut thickness 60 μm, ø 3.5-4.0 mm strut thickness 80 μm; c. Images: Secco G et al. Time-related changes in neointimal tissue coverage following a new generation SES implantation: an OCT observational study. Presented at: euro PCR, May 20, 2014; Paris, France; d. Clinical data collected with the Orsiro DES device within the Orsiro DES family clinical program; e. Clinical data collected with the Orsiro Mission DES device within the Orsiro DES family clinical program; f. At 5-year in STEMI patients; g. As per IFU: ACS - Acute Coronary Syndrome; B2/C - Complex Lesions; DAPT - Dual Antiplatelet Therapy; DM - Diabetes Mellitus; HBR - High Bleeding Risk; MVD - Multi-Vessel Disease; STEMI - ST-Elevation Myocardial Infarction; SV -Small Vessels; h. Compared to Xience, up to 5 years. Orsiro DES: 7.7%, Xience DES: 11.1%, BIOSTEMI with historical information RR, 0.70; 95% BCI, 0.51-0.95, Bayesian posterior probability, 0.988; i. Please refer to the IFU for indications and post-procedure antiplatelet therapy recommendations; 

1. Iglesias JF. et al, Long-term outcomes with biodegradable polymer sirolimus eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomized superiority trial, The Lancet, 2024; 2. In comparison to Xience Sierra, Resolute Onyx and Synergy for bench tests on pushability, trackability and crossability, BIOTRONIK data on file; 3. In comparison to Resolute Onyx, Xience Sierra and Synergy. BIOTRONIK data on file; 4. As characterized with respect to strut thickness in Bangalore et al. Meta-analysis; 5. Secco G et al. Time-related changes in neointimal tissue coverage of a novel Sirolimus eluting stent: Serial observations with optical coherence tomography. Cardiovascular Revascularization Medicine 17.1 (2016): 38-43; 6. Stefanini GG et al. Coronary stents: novel developments. Heart. 2014 Jul 1;100(13):1051-61; 7. Low AF. Stent platform for procedural success: Introducing the Continuous Sinusoidal & Core Wire Technologies. Presented at: AsiaPCR; 22-24 January, 2015; Singapore, Singapore; 8. Tolentino A. Evolving DES Strategy: Biodegradable Polymer vs. Bioabsorbable Scaffold. Presented at: Cardiovascular Nurse/Technologist Symposium; June 17, 2016; New York, USA; 9. Based on investigator’s interpretation of BIOFLOW-V primary endpoint results; 10. In large RCTs, based on Taglieri et al. Meta-analysis, against currently used DES; 11. Including Orsiro DES and Orsiro Mission DES, BIOTRONIK data on file, as of February 2023; 12. Based on TLF primary endpoint. Iglesias, JF. et al. Long-term outcomes with biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomized superiority trial, presented at TCT 2023; 13. Based on primary and secondary outcomes in BIOFLOW-DAPT RCT, Valgimigli M et al. Circulation 2023 Aug 25

Orsiro, Orsiro Mission, proBIO and BIOlute are trademarks or registered trademarks of the BIOTRONIK Group of Companies. All other trademarks are the property of their respective owners. 

© 2025 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.